Who are Liraglutid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adlyxin, Albugon, Byetta, Byetta, Mounjaro, Victoza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liraglutid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Liraglutid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liraglutid (Liraglutid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Glucagon-like peptide 1 receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Liraglutid (Liraglutid) — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Liraglutid TARGET	Liraglutid	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed		Glucagon-like peptide 1 receptor
Adlyxin	LIXISENATIDE	Sanofi-Aventis Us Llc	marketed	Insulin Analog [EPC]	Glucagon-like peptide 1 receptor	2016-01-01
Albugon	ALBIGLUTIDE	GSK	marketed	GLP-1 Receptor Agonist	Glucagon-like peptide 1 receptor	2014-01-01
Byetta	Byetta	AstraZeneca	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01
Byetta	EXENATIDE	AstraZeneca	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01
Mounjaro	Mounjaro	Nicholas Skertich	marketed		Gastric inhibitory polypeptide receptor, Glucagon-like peptide 1 receptor
Victoza	liraglutide	Novo Nordisk	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-08-18 — Byetta · 9884092 · US
2026-08-18 — Byetta · 8906851 · US
2026-08-18 — Byetta · 8329648 · US
2027-02-18 — Byetta · 9884092*PED · US
2027-02-18 — Byetta · 8906851*PED · US
2027-02-18 — Byetta · 8329648*PED · US
2027-06-20 — Byetta · 8501698 · US
2027-11-12 — Byetta · 8758292 · US
2027-12-20 — Byetta · 8501698*PED · US
2028-01-12 — Byetta · 8216180 · US
2028-03-21 — Byetta · 8361972 · US
2028-03-25 — Byetta · 9320853 · US
2028-03-25 — Byetta · 8439864 · US
2028-05-12 — Byetta · 8758292*PED · US
2028-07-12 — Byetta · 8216180*PED · US
2028-09-21 — Byetta · 8361972*PED · US
2028-09-25 — Byetta · 9320853*PED · US
2028-09-25 — Byetta · 8439864*PED · US
2029-02-04 — Byetta · 8827963 · US
2029-05-19 — Byetta · 8690837 · US
2029-08-04 — Byetta · 8827963*PED · US
2029-11-19 — Byetta · 8690837*PED · US
2030-01-07 — Byetta · 8998876 · US
2030-01-18 — Byetta · 8721615 · US
2030-07-07 — Byetta · 8998876*PED · US
2030-07-18 — Byetta · 8721615*PED · US
2030-10-04 — Byetta · 8895033 · US
2031-04-04 — Byetta · 8895033*PED · US
2037-01-09 — Victoza · 9968659 · Method of Use · US
2037-07-09 — Victoza · 9968659*PED · Compound · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Liraglutid — Competitive Intelligence Brief. https://druglandscape.com/ci/liraglutid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing